+
IMAGING ENDPOINTS

IMAGING ENDPOINTS is a full-service Imaging Contract Research Organization providing services to the pharmaceutical and medical device industries to accelerate their national and international oncology clinical trials. Extensive expertise in Cancer Imaging allows Imaging Endpoints to perform qualitative and quantitative assessments of both anatomic and physiologic/metabolic imaging modalities in order to evaluate the effectiveness of new therapeutics.

+
STUDYLOG

STUDYLOG provides animal study management solutions to commercial and academic research organizations. Studylog enables organizations to efficiently manage study conduct and study data within a searchable and accessible framework. Organizations can now centrally store and index the institutional knowledge that usually resides in notebooks and the memories of individual researchers.

+
THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGen)

THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGen) is a non-profit 501(c)(3) organization focused on developing earlier diagnostics and smarter treatments. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process.

+
21ST CENTURY ONCOLOGY

21ST CENTURY ONCOLOGY is the foremost provider of cancer care services across multiple modalities, and the largest radiation oncology provider. For more than 30 years, 21st Century Oncology has been committed to providing state-of-the-art, academic level treatment options in a patient-centric setting focused on continuous innovation. 21st Century Oncology employs or is affiliated with hundreds of physicians in a broad spectrum of cancer-related specialists--working together to deliver the most advanced integrated cancer care.

+
MEDICAL PROGNOSIS INSTITUTE (MPI)

MEDICAL PROGNOSIS INSTITUTE (MPI) was founded to improve the efficacy of cancer drugs through its Multi Biomarker technology called Drug Response Predictor (DRP). DRP is a validated, unique Multi Biomarker built on an algorithm from Big Data derived from human cancer tissue. DRP can be added to and will strengthen existing tools already being used in the drug development field.